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Abstract
Skeletal muscle regeneration by muscle satellite cells is a physio-
logical mechanism activated upon muscle damage and regulated
by Notch signaling. In a family with autosomal recessive limb-
girdle muscular dystrophy, we identified a missense mutation in
POGLUT1 (protein O-glucosyltransferase 1), an enzyme involved in
Notch posttranslational modification and function. In vitro and
in vivo experiments demonstrated that the mutation reduces O-
glucosyltransferase activity on Notch and impairs muscle develop-
ment. Muscles from patients revealed decreased Notch signaling,
dramatic reduction in satellite cell pool and a muscle-specific a-
dystroglycan hypoglycosylation not present in patients’ fibroblasts.
Primary myoblasts from patients showed slow proliferation, facili-
tated differentiation, and a decreased pool of quiescent PAX7+
cells. A robust rescue of the myogenesis was demonstrated by
increasing Notch signaling. None of these alterations were found
in muscles from secondary dystroglycanopathy patients. These
data suggest that a key pathomechanism for this novel form of
muscular dystrophy is Notch-dependent loss of satellite cells.
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Introduction
Cell surface glycans are diverse in structure and function and play
critical roles in many biological processes including infection,
cancer, and development (2009). Broadly speaking, glycans affect
the function of proteins to which they are linked by modulating
their structure and/or by serving as a direct recognition signal for
other proteins (Varki & Sharon, 2009). Glycans are involved in
protein folding, stability, and trafficking and regulate the activity of
important signaling pathways such as Notch, WNT, BMP, and
Hedgehog (Christian, 2000; Yan & Lin, 2009; Jafar-Nejad et al, 2010;
Takeuchi & Haltiwanger, 2014). Not surprisingly, aberrant glycosy-
lation leads to a variety of human diseases, the list of which is grow-
ing (Freeze et al, 2014).
Protein glycosylation can directly regulate signaling events. A
clear example of this is the regulation of the evolutionarily
conserved Notch signaling pathway, which is an intercellular
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communication mechanism widely used during animal development
(Hori et al, 2013). The extracellular domain of the Notch receptor is
modified with O-fucose and O-glucose glycans (Moloney et al,
2000). The structures of these glycans change in a tissue-specific and
developmentally regulated manner (Johnston et al, 1997), and alter-
ing Notch glycosylation dramatically affects its activity (Stanley &
Okajima, 2010; Takeuchi & Haltiwanger, 2010). One of the cell types
whose regulation by Notch signaling has been intensely studied in
recent years is the muscle-specific adult stem cell called the satellite
cell (SC) (Mourikis & Tajbakhsh, 2014). SCs reside between the basal
lamina and sarcolemma of myofibers (Mauro, 1961) and are the
primary contributors to skeletal muscle growth and repair (Collins
et al, 2005). Despite continuous regeneration, pools of SC are
maintained in healthy muscle. This is accomplished through asym-
metric cell divisions of SC, which give rise both to self-renewing
SC and to committed myogenic progenitors that differentiate
(Kuang et al, 2007; Sacco et al, 2008). In this process, the Notch
pathway is key for maintaining quiescence in SC and for homing
of SC-derived myoblasts (Bjornson et al, 2012; Brohl et al, 2012).
A recent report indicates that mice in which Notch signaling is
specifically blocked in SCs exhibit a decrease in the number of SCs
and histological features of muscular dystrophy even upon normal
daily activity (Lin et al, 2013), suggesting that Notch-mediated
maintenance of an active SC pool is essential for repairing muscle
damage caused by regular activity and for maintaining healthy
muscle. Muscular dystrophies are inherited disorders characterized
by progressive weakness due to skeletal muscle degeneration, due
to mutations in a growing list of responsible genes (Chandrasekharan
& Martin, 2010; Rahimov & Kunkel, 2013). However, to date, no
primary molecular defects in SC or Notch pathway components
have been identified in human muscular dystrophies.
Mutations in several genes disrupt various aspects of the
dystrophin-associated glycoprotein complex, which links the
cytoskeleton to the extracellular matrix in muscle (Chandrasekharan
& Martin, 2010). A key component of this complex is dystroglycan
(Ervasti et al, 1990), a transmembrane protein essential for normal
basement membrane development and muscle maintenance.
Dystroglycan comprises a transmembrane b-subunit non-covalently
linked to an extracellular a-subunit containing a mucin-like
domain, which is modified with numerous O-linked glycans (Bar-
resi & Campbell, 2006). The b-subunit is linked to the actin
cytoskeleton, and the O-linked glycans on the a-subunit are critical
for its binding capacity to extracellular matrix proteins such as
laminin and agrin (Ervasti & Campbell, 1993; Michele et al, 2002).
Mutations in dystroglycan itself result in the primary dystrogly-
canopathies (Henry & Campbell, 1998; Cote et al, 1999; Hara et al,
2011; Willer et al, 2014; Riemersma et al, 2015; Kanagawa et al,
2016). Secondary dystroglycanopathies are caused by interruption
of a-dystroglycan–ligand interactions due to mutations in a grow-
ing list of genes [currently eighteen (Bonnemann et al, 2014)]
encoding glycosyltransferases and accessory proteins responsible
for a-dystroglycan’s extensive posttranslational modifications
(Muntoni et al, 2011; Inamori et al, 2012; Yoshida-Moriguchi et al,
2013). These include protein O-mannosyltransferase 1 (POMT1)
and POMT2, which add O-linked mannose to a-dystroglycan
(Manya et al, 2004; Willer et al, 2004), and like-acetylglucosami-
nyltransferase (LARGE), which is responsible for the addition of
repeating xylose-glucuronic acid units on the O-mannosyl glycans
on a-dystroglycan (Inamori et al, 2012). The dystroglycan gene
(DAG1) is expressed in SCs (Cohn et al, 2002), but glycosylated
a-dystroglycan is not required by myogenic cells during prolifera-
tion (Awano et al, 2015), a notion supported by the observation
that trace amounts of glycosylated a-dystroglycan are found in
C2C12 and human primary myoblasts during proliferation. Cultures
of freshly isolated muscle fibers suggest that glycosylation of
a-dystroglycan is needed for proliferation of SCs in vivo, but it is
not necessary when SCs are removed from their niche (Ross et al,
2012). The transition to larger glycans occurs rapidly after differen-
tiation is induced, and a direct correlation exists between
LARGE-dependent extension of O-glycans on a-dystroglycan and its
function as an extracellular matrix receptor (Goddeeris et al,
2013). Despite extensive studies regarding the genetics of dystro-
glycanopathies, the responsible gene is still unknown in a signifi-
cant number of patients; thus, mutations in additional genes will
likely be implicated in this group of diseases.
Here, we report a homozygous missense mutation (D233E) in
the protein O-glucosyltransferase 1 gene, POGLUT1, in four siblings
with autosomal recessive limb-girdle muscular dystrophy. POGLUT1
is the sole enzyme that directly adds O-glucose to a distinct serine
residue of epidermal growth factor-like (EGF) repeats containing a
CXSX(P/A)C consensus sequence (Rana et al, 2011), many of which
are found in Notch extracellular domains (Fernandez-Valdivia et al,
2011; Rana et al, 2011). The D233E mutation dramatically reduces
the O-glucosyltransferase activity of POGLUT1, leading to impaired
Notch signaling and a dramatic decrease in the number of SCs in
adult muscles. Transgenic experiments in Drosophila indicate that
D233E impairs the ability of human POGLUT1 to rescue the muscle
phenotype caused by the loss of fly Poglut1 activity. Patient muscles
show a-dystroglycan hypoglycosylation and decreased binding to
laminin, but normal binding to agrin and normal basement
membrane structure. Moreover, unlike other dystroglycanopathies,
patient fibroblasts exhibit normal a-dystroglycan glycosylation and
laminin binding. Together, our findings indicate that exhaustion of
the SC pool plays a primary role in this novel form of muscular
dystrophy.
Results
Clinical and radiological findings
A consanguineous family from southern Spain comprises 17 indi-
viduals spanning three generations (Fig 1A). Four out of five
siblings from generation II presented a phenotype consistent with a
limb-girdle muscular dystrophy. Specifically, the patients exhibited
muscle weakness predominantly in the proximal lower limbs, with
onset during the third decade. The disease course was progressive,
leading to scapular winging and wheelchair confinement. For more
extended clinical data regarding this family, see the Appendix Infor-
mation, Appendix Fig S1, and Appendix Tables S1 and S2. Serum
creatine kinase level was normal in three patients and mildly
elevated in one (Appendix Table S1). Muscle biopsies from all four
affected siblings revealed histological features ranging from very
mild myopathic changes to classic dystrophic pathology (Fig 1A).
Proteins typically affected in myopathies displayed normal
expression in muscle, except for a reduction in a-dystroglycan
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(Appendix Fig S2). Muscle magnetic resonance imaging (MRI) of
the legs revealed a striking pattern of muscle involvement (Fig 1C),
with early fatty replacement of internal regions of thigh muscles
that spared external areas. This “from inside-to-outside” mode of
fatty degeneration progressed over the years and did not match the
distribution patterns typically associated with other forms of
muscular dystrophies (Appendix Information and Appendix Figs S3
and S4).
Expression and functional modification of a-dystroglycan
in patients
Given the key role played by aberrant a-dystroglycan glycosylation
and function in a subset of muscular dystrophies and because of the
observed decrease in a-dystroglycan levels in patient muscles, we
examined the glycosylation status and ligand-binding ability of
a-dystroglycan in our patients. Immunofluorescence staining of
frozen cross sections from skeletal muscle biopsy with an antibody
against glycosylated a-dystroglycan [IIH6 (Ervasti & Campbell,
1991)] revealed a variable reduction in the glycosylated form of
a-dystroglycan at the sarcolemma in patients, while antibodies
against a-dystroglycan core protein, b-dystroglycan, and laminin a2
showed normal staining (Fig 2A and Appendix Fig S5A). In agree-
ment with this observation, Western blots showed a reduction in
a-dystroglycan glycosylation in patient muscle, accompanied by a
mild decrease in the molecular weight of glycosylated a-dystro-
glycan compared with controls. To examine whether decreased
a-dystroglycan glycosylation affected binding to ligands, we
performed a ligand overlay assay. As shown in Fig 2B, the laminin-
binding activity was diminished in muscle. However, the agrin-
binding activity to the patients’ muscle extracts showed no
difference compared with controls (Fig 2B). Moreover, in skin
fibroblasts from patients, the level of both functional a-dystroglycan
glycosylation, examined by Western blot and flow cytometry
(Stevens et al, 2013b), and its ability to bind laminin (Fig 2B and
Appendix Fig S5B) were normal, unlike known secondary dystrogly-
canopathies, which usually result in decreased functional a-dystro-
glycan glycosylation in both muscle and the skin fibroblasts (Willer
et al, 2012; Carss et al, 2013; Stevens et al, 2013a). Finally,
although basement membrane defects are commonly observed in
dystroglycanopathies (Yamamoto et al, 1997; Goddeeris et al,
2013), transmission electron microscopy showed normal muscle
ultrastructure in patients, with no alterations in basement
membrane compaction (Fig 2C and Appendix Fig S5C).
A
B C
Figure 1. POGLUT1 missense mutation in a family with a limb-girdle muscular dystrophy.
A The family pedigree, where circles denote female members, squares male members, solid symbols affected members, and white symbols asymptomatic members with
normal physical exam; the dots indicate heterozygous carriers, and double line denotes a consanguineous marriage. The pictures show scapular winging, which is a
consistent clinical sign in affected individuals.
B Hematoxylin and eosin staining (H&E) of skeletal muscle from patient II.1 shows histological features of moderate-to-severe dystrophic pattern. Scale bar, 50 lm.
C T1-weighted MRI axial images at thigh and calf levels show that the fatty degeneration is more prominent in thigh muscles, equally affecting posterior and anterior
compartments, with relative sparing of the rectus femoris, sartorius, and gracilis muscles until late stages (4, 10, and 11, respectively). Strikingly, the fatty tissue is
located in the internal parts of almost all the affected muscles in thigh (1, 2, 3, 5–9), while the external regions are spared. At calf level, only the gastrocnemius
medialis muscle (12) shows this pattern, while the soleus (13) is diffusely involved. Patient II.2 (PII.2) shows late-stage thigh muscles with an unusual involvement of
the tibialis posterior muscle (14) in the lower leg.
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These observations suggest that although a partial decrease in
a-dystroglycan functional glycosylation is detected in muscle from our
patients, decreased a-dystroglycan glycosylation is unlikely to be caused
by the same pathomechanism seen in secondary dystroglycanopathies
and that a mutation in a gene other than the enzymes directly involved
in a-dystroglycan glycosylation might underlie this disease.
D233E mutation in POGLUT1
Homozygosity mapping in DNA samples through genomewide geno-
typing arrays containing ~ one million single nucleotide polymor-
phisms (SNPs) revealed a unique (> 500 kb) region of homozygosity
identical by descent in the four affected siblings and absent in their
A
C
B
Figure 2. A muscle-specific decrease in a-dystroglycan glycosylation and laminin binding upon POGLUT1 mutation.
A Muscle sections show variable labeling using an antibody against glycosylated a-dystroglycan (aDG-IIH6), whereas labeling using antibodies against a-dystroglycan
core protein (aDG-Core), b-dystroglycan (bDG), and laminin-a2 is similar to control (scale bar, 100 lm).
B Western blots and ligand overlay (O/L) of wheat germ agglutinin-enriched muscle and fibroblasts lysates from PII.2, PII.5, the healthy sibling (HII.3), and healthy
controls (Ctr, Ctr1, and Ctr2) (muscle: 250 lg protein/lane, fibroblasts: 800 lg/lane). In muscle, expression of aDG-IIH6 is reduced, but the aDG-Core shows similar
expression as controls, with a slight reduction in molecular weight; laminin overlay assay detected some binding activity but was diminished compared with controls,
whereas agrin-binding activity showed no difference with controls. In fibroblasts, both aDG-IIH6 and aDG-Core expression and laminin-binding activity were normal,
suggesting that unlike other muscular dystrophies, a-dystroglycan glycosylation defect is muscle specific in POGLUT1 patients.
C No ultrastructural alterations are observed in muscle by electron microscopy (6–7 fields were captured from PII.1, PII.3, and PII.5). Note normal basement membrane
compaction (arrowheads). Original magnification: ×26,700.
Source data are available online for this figure.
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healthy sister (Fig 3A). This 14.6 megabase region on chromosome
3q13.13-q21.2, defined by SNP markers rs13081374 and rs2333038,
included 112 protein-coding genes (Fig 3B and C). No structural
genomic variations were shared by affected family members, thus
excluding gross gene dosage change as a cause of disease. We next
performed whole exome sequencing of patients II.4, II.5, and their
healthy sister II.3 and found a c.699T > G transversion within
POGLUT1 (Fig 3D). The polymorphism produces an aspartic-to-
glutamic substitution at amino acid residue 233 (p.D233E), which
passed all possible filtering, segregated with the disease, and conse-
quently was suspected to be the causal genetic alteration.
Significantly, POGLUT1 is located within the 3q13.13-q21.2
region of homozygosity in the affected siblings (Fig 3C). The muta-
tion was not found in the Exome Aggregation Consortium (ExAC)
database (http://exac.broadinstitute.org) [accessed in February
2015], thus discarding this genetic variant in 60,698 individuals
(36,673 Europeans). In addition, the D233E mutation was further
excluded in 919 DNA samples from 57 populations worldwide
(Appendix Table S3).
The mutated aspartic acid residue is located in the capsule-asso-
ciated protein (CAP)10 domain, 14 amino acids apart from the puta-
tive ERD catalytic motif, and is highly conserved across vertebrate
species (Fig 3E).
Expression of POGLUT1D233E in patients
We assessed the effect of the D233E mutation on the expression of
POGLUT1 in samples from patients. In skeletal muscle, Western blot
showed normal protein expression and qRT–PCR assays showed no
difference in the POGLUT1 mRNA level compared with controls. In
skin biopsy-derived fibroblasts, immunostaining revealed a colocal-
ization of POGLUT1D233E with the endoplasmic reticulum, display-
ing the same pattern as the wild-type POGLUT1 in human control
fibroblasts (Appendix Fig S6). These data indicate that the D233E
mutation does not affect the expression level or subcellular localiza-
tion of POGLUT1.
Biochemical assays of D233E mutation in POGLUT1
We next analyzed the effect of the D233E mutation on the O-gluco-
syltransferase activity of POGLUT1 by biochemical assays. Wild-
type and D233E mutant forms of human-POGLUT1 were transiently
expressed in HEK293T cells and purified from the culture media
(Appendix Fig S7A). We examined the enzymatic activity of purified
proteins toward a known substrate: bacterially expressed epidermal
growth factor-like (EGF) repeat from human coagulation factor IX
(hFIX). POGLUT1D233E mutant showed significantly lower activity
than wild type (Fig 4A). O-glucosyltransferase activity was depen-
dent on the concentrations of EGF repeat and UDP-glucose (acceptor
and donor substrate, respectively). POGLUT1D233E also showed
lower activity than wild type toward five different single EGF
repeats from mouse Notch1 (Fig 4B), suggesting that the mutation
affects O-glucosylation of all EGF repeats containing the O-glucose
consensus sequence (CXSX(P/A)C) (Rana et al, 2011). Prior work
has shown that POGLUT1 also has protein O-xylosyltransferase
activity toward certain EGF repeats with a diserine motif within the
O-glucose consensus sequence (e.g. EGF16 of mouse Notch2)
(Takeuchi et al, 2011). POGLUT1D233E mutant also showed lower
O-xylosyltransferase activity than wild type (Appendix Fig S7B). To
examine whether POGLUT1D233E retains any enzymatic activity, we
performed overnight incubation and then analyzed the products by
reverse-phase HPLC and mass spectrometry. Both wild type and the
D233E mutant added a single glucose or xylose to the hFIX-EGF
repeat (Fig 4C) or EGF16 from mouse Notch2 (Appendix Fig S7C),
indicating that POGLUT1D233E has residual enzymatic activity.
Analysis of Notch signaling pathway and satellite cells in
D233E patients
Mutations in the Drosophila gene rumi, which encodes the fly-
POGLUT1, result in a temperature-sensitive loss of Notch signaling
(Acar et al, 2008). Moreover, Poglut1 knockdown in mouse
myoblast C2C12 cells results in a significant decrease in O-glucosyl-
transferase activity and impaired Notch signaling (Fernandez-
Valdivia et al, 2011). Accordingly, we examined the expression of
activated Notch and the levels of Notch downstream targets in
patient muscles. Decreases in Notch1-intracellular domain expres-
sion and in HES1 mRNA levels in skeletal muscle were detected
compared with controls, which support that D233E affects Notch
activity (Fig 5A and B). Notch signaling is critical in normal postna-
tal myogenesis by regulating SC maintenance (Bjornson et al,
2012), at least in part by directly inducing the expression of Pax7,
which encodes a transcription factor critical for the maintenance of
adult SC (Olguin & Olwin, 2004). Indeed, treating proliferating
C2C12 cells with the c-secretase inhibitor DAPT, which blocks
Notch signaling, significantly reduced the mRNA levels of Pax7
(Appendix Fig S8). Likewise, we found a decrease in PAX7 mRNA
and fewer PAX7+ cells in the muscle of patients compared with
controls (Fig 5C and D). Together, these observations suggest that
the D233E mutation affects the self-renewal of SC by reducing Notch
signaling, likely due to defective O-glucosylation.
We analyzed the same parameters in patients suffering from
other muscular dystrophies, and also in patients suffering from a
secondary dystroglycanopathy, whose muscle biopsies showed
mild-to-moderate dystrophic changes, similar to our patients. Both
groups show significantly higher levels of activated Notch and
higher numbers of PAX+ cells compared with D233E patients
(Appendix Fig S9A–H). These data support the notion that the
observed decrease in Notch1 signaling and PAX7+ cells in D233E
patients is not secondary to a-dystroglycan hypoglycosylation.
In vivo functional study of POGLUT1D233E
To investigate the in vivo effects of the D233E mutation on
POGLUT1 function in muscle progenitors, we performed cross-
species rescue experiments in the context of adult myogenesis in
Drosophila, a process regulated by Notch signaling (Gildor et al,
2012). In these experiments, we used the rumi79 allele, which
harbors a missense mutation that abolishes fly-POGLUT1 enzymatic
activity but does not affect its expression (Acar et al, 2008). When
raised at 18°C, rumi79/79 animals exhibited normal indirect flight
muscle development and a large number of myoblasts expressing
the transcription factor Twist, which is a downstream target of
Notch activation (Fig 6A–B″). However, when rumi79/79 animals
were raised at 25 and 30°C during the early pupal stage, when these
muscles form, muscle development was dramatically impaired and
ª 2016 The Authors EMBO Molecular Medicine Vol 8 | No 11 | 2016
Emilia Servián-Morilla et al POGLUT1 gene mutation and muscular dystrophy EMBO Molecular Medicine
1293
the number of Twist+ myoblasts was severely decreased (Fig 6C–D″).
The severe temperature-sensitive defects observed in indirect
flight muscle development in rumi79/79 animals indicate that adult
myoblast development in flies depends on the enzymatic activity of
fly-POGLUT1. Overexpression of wild-type human-POGLUT1-FLAG
in muscle progenitors rescued the muscle phenotypes of rumi79/79
A
C
D E
B
Figure 3. POGLUT1 D233E mutation in patients.
A Genomewide mapping through high-density genotyping. The structural genomic variation and extended regions of homozygosity (loss of heterozygosity [LOH]) over
the entire genome is shown for individuals II.1 to II.5. The homozygosity segment shared by the four affected siblings in chromosome 3 is indicated with an arrow.
B This region is represented in more detail, where extended regions of homozygous genotypes in contiguous biallelic polymorphisms are highlighted with a green
background.
C The 14.6 megabase region of homozygosity that is shared by all affected siblings is highlighted by vertical red lines in (B), and genes within this genomic region are
shown. Note that POGLUT1 gene is underlined.
D Chromatograms reveal a homozygous T-to-G substitution (black boxes and arrowheads) in the four affected family members, while a heterozygous G/T in the healthy sibling.
E Schematic structure of the human POGLUT1 protein, which contains a signal peptide (SP), a CAP10 domain, and a Lys-Asp-Glu-Leu (KDEL)-like endoplasmic reticulum
retention signal. D233E is located in the CAP10 domain (arrow), close to the predicted ERD catalytic motif (asterisk). Alignment of amino acids flanking the mutated aspartic
acid from POGLUT1 orthologs indicates evolutionary conservation of D233 in vertebrates (open arrowhead). Black boxes denote similarity of amino acid residues.
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animals (Fig 6E). However, the overexpression of human-
POGLUT1D233E-FLAG only showed a weak and variable rescue of
the muscle morphology and myoblast numbers in rumi79/79 animals
(Fig 6F–H), indicating that this mutation significantly decreases the
ability of POGLUT1 to promote muscle development and Notch
signaling in myoblasts. It is interesting to note that fly-POGLUT1
harbors a glutamic acid (E) at position 252, which is equivalent to
D233 in human-POGLUT1 (Fig 3E). Given the robust protein O-
glucosyltransferase activity of the fly-POGLUT1 and because 35% of
the amino acids in the CAP10 enzymatic domains of human and fly
POGLUT1 are divergent (Acar et al, 2008), other amino acid dif-
ferences between these two proteins are likely to be the reason why
the fly protein is fully functional despite harboring the equivalent of
the D233E mutation.
Ex vivo analysis of D233E primary myoblasts
Previous studies have shown that the Notch signaling pathway not
only plays an important role in maintaining satellite cell quiescence,
but also enhances myoblast proliferation and inhibits myogenic dif-
ferentiation (Conboy & Rando, 2002; Bjornson et al, 2012; Mourikis
& Tajbakhsh, 2014).
In order to directly test our hypothesis that the decrease in the
POGLUT1 enzymatic activity caused by the D233E mutation
disrupts muscle cell function, we explored myogenesis in D233E
primary myoblasts from patient muscle biopsies compared with
healthy and disease controls (Appendix Fig S10). We quantified the
percentage of self-renewing, proliferating, and differentiating cells
based on PAX7 and MyoD expression. Quantitative analysis in
myoblasts cultured in a growth medium revealed that the percent-
age of PAX7+MyoD+ (proliferating) cells in D233E cells was signifi-
cantly lower than those in healthy and disease controls (Fig 7A–C).
The percentage of PAX7+ cells and PAX7+MyoD (self-renewing)
cells was significantly decreased in D233E samples (Fig 7D and E),
whereas the percentage of PAX7MyoD+ (differentiating) cells was
increased (Fig 7F). When myoblasts reached confluence, they were
cultured in a differentiation medium. We observed more efficient
myoblast fusion into the multinucleated myotubes and higher levels
of myogenin expression in D233E cultures compared with controls
(Fig 7G–I). The slow proliferation and facilitated differentiation of
mutant myogenic cells are in agreement with decreased Notch activ-
ity in the muscle of D223E patients.
Due to the scarcity of cells obtained from fresh patient’s muscles
in culture (likely because of the severe defect in proliferation of
D233E myoblasts), we performed immortalization of the primary
myoblasts (Mamchaoui et al, 2011), and conversion of skin fibrob-
lasts from patients to myogenic cells by transduction of inducible
MyoD (Choi et al, 1990). Thus, we generated two different continu-
ous myogenic cell lines with the D233E mutation, which showed
similar phenotypic features, although PAX7 expression started after
1–3 days in culture in the myogenic cell line (Appendix Figs S11
and S12). To examine whether increasing Notch pathway activity
can rescue the alterations of the myogenic process observed in
D233E immortalized myoblasts during differentiation in culture, we
used lentivirus to overexpress NICD1 in these cells and observed a
solid reversion of the proliferation defects (Fig 8A and B,
Appendix Fig S13A and B). However, we did not observe rescue of
the amount of PAX7+ cells (Fig 8C). It has been described that the
effect of Notch on the expression of PAX7 in myogenic cell lines
such as C2C12 is not as potent as in primary myoblasts (Sun et al,
2008). This probably hindered the modification of PAX7 expression
during the rescue experiment. In addition, NICD1 overexpression
robustly rescued the facilitated differentiation shown by D233E
myoblasts in culture (Fig 8D, Appendix Figs S13C and S14), and this
A
B
C
Figure 4. POGLUT1D233E has lower enzymatic activity than wild type.
A Protein O-glucosyltransferase activity of wild-type (WT) or D233E mutant
POGLUT1 protein toward human factor IX EGF repeat (hFIX-EGF). Wild type
shows higher O-glucosyltransferase activity than D233E, and this activity is
dependent on the concentration of the acceptor substrate hFIX-EGF repeat
(left) and on the concentration of donor substrate UDP-glucose (UDP-Glc)
(right). Values indicate mean  SEM from three independent assays.
B O-Glucosyltransferase activity toward five different single EGF repeats from
mouse Notch1. Wild-type POGLUT1 shows higher activity toward all EGF
repeats tested than POGLUT1D233E. The y-axis shows the normalized activity
relative to wild-type POGLUT1. EGF repeats were at 10 lM. Values indicate
mean  SEM from three independent assays.
C Elution profiles of the POGLUT1 reaction products on reverse-phase HPLC.
hFIX-EGF repeat was incubated with wild-type or D233E mutant POGLUT1
and donor substrate, UDP-Glc or UDP-xylose (UDP-Xyl), at 37°C overnight.
Values on top of the peaks indicate the measured masses. Addition of Glc
(162 Da) or xylose (132 Da) to hFIX-EGF (5696.2 Da) by wild-type POGLUT1
caused a shift to an earlier retention time (left). Similarly, the products
exhibited a similar shift after incubation with POGLUT1D233E (right). These
results indicate that POGLUT1D233E can add a single glucose or xylose to
hFIX-EGF repeats and thus has residual enzymatic activity.
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rescue was demonstrated by the fusion index (Fig 8E) and expres-
sion of myogenin (Fig 8F). These results support the pathogenic role
of decreased Notch signaling in this novel muscular dystrophy.
Role of Notch on a-dystroglycan glycosylation
As shown in Fig 2, our patients exhibit a muscle-specific reduction
in a-dystroglycan glycosylation. The only known protein domain to
which POGLUT1 can add carbohydrates is a properly folded EGF
repeat containing the CXSX(P/A)C consensus sequence (Takeuchi
et al, 2012). Since a-dystroglycan contains no EGF repeats nor CXSX
(P/A)C sites, it is unlikely to be a direct target of glycosylation by
POGLUT1. A recent study has shown that in transgenic mice and
C2C12 myoblasts, a-dystroglycan glycosylation is a progressive
process that initiates rapidly after myoblasts are induced to differen-
tiate, and exhibits a regular and gradual transition to a larger glyco-
forms to reach the normal level after 5 days of differentiation
(Goddeeris et al, 2013). In order to evaluate this progressive pattern
of a-dystroglycan glycosylation, primary immortalized myoblasts
were differentiated. After 5 days with differentiation medium,
D233E myoblasts showed a lower level and irregular progression
profile of a-dystroglycan glysosylation compared with controls,
which reproduced the same pattern previously demonstrated in
C2C12 cells (Goddeeris et al, 2013) (Fig 9A). These observations
are compatible with abnormal differentiation dynamics in patient
myoblasts. Given the well-established role of Notch signaling in
A
D
B C
Figure 5. Muscles from D233E patients show decreased Notch signaling and pool of satellite cells.
A Western blot of muscle homogenates shows reduced expression of Notch1 intracellular domain (NICD) in patients.
B, C qRT–PCR on RNA extracted from skeletal muscle shows that expression of HES1 (B) and PAX7 (C) was significantly lower in D233E patients compared with healthy
controls. Mean  SEM; Student’s t-test (B) and Mann–Whitney U-test (C).
D PAX7+ cells in skeletal muscle sections, demonstrating that satellite cells are less abundant in D233E patients than in controls (n = 3 muscles with 10–15 fields
analyzed per muscle). Mean  SEM; Mann–Whitney U-test; scale bar, 50 lm.
Source data are available online for this figure.
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muscle differentiation, we hypothesized that decreased Notch
signaling in D233E patients’ myoblasts might contribute to altered
a-dystroglycan glycosylation. We first attempted to test this
hypothesis by asking whether NICD overexpression can restore
a-dystroglycan glycosylation in patient myoblasts. However, given
the strong inhibition of differentiation upon NICD overexpression,
A A′ A′′ E E′ E′′
F F′ F′′
G
H
G′ G′′
B B′ B′′
C C′ C′′
D D′ D′′
Figure 6. Loss of Rumi results in temperature-sensitive Drosophila muscle defects and is only weakly rescued by POGLUT1D233E expression.
A–A″ Staining of Drosophila indirect flight muscles at 25% pupal development with 22C10 antibody (myotube marker) and anti-Twist antibody (myoblast marker)
indicates that in wild-type animals, indirect flight muscles are formed from six myotubes, and a large number of Twist+ myoblasts are present.
B–B″ rumi79/79 mutants raised at 18°C show no obvious defects in myoblast number or myotube morphology.
C–D″ rumi79/79 mutants exhibit decreased number of myoblasts at 25–30°C and either an incomplete set of short myotubes when raised at 25°C or aberrant
morphology of myotubes when raised at 30°C.
E–E″ rumi79/79 animals overexpressing FLAG-tagged POGLUT1WT in the muscle compartment using Mef2-GAL4 and raised at 25°C during the pupal stage show a rescue
of the rumi79/79 muscle phenotype.
F–G″ Overexpression of FLAG-tagged POGLUT1D233E only partially rescues the rumi79/79 muscle phenotype, with some variation in the myotube length and the number
of restored Twist+ cells (compare G and F). Note that the number of Twist+ cells restored by POGLUT1D233E is much smaller than that restored by POGLUT1WT.
H Quantification of myotube lengths in rumi79/79 mutants with or without POGLUT1 expression indicates a weak rescue of the phenotypes by POGLUT1D233E
compared with POGLUT1WT. The differences in myotube lengths are statistically significant. For rumi79/79 rescue (left bar), 5 animals were used and a total of 23
myotubes were measured; for D233E rescue, 11 animals and 54 myotubes; for WT rescue, 5 animals and 22 myotubes. Mean  SD is shown; one-way ANOVA with
Bonferroni’s multiple comparisons test.
Data information: Scale bar in (A0) is 50 lm and applies to (A–G″).
Source data are available online for this figure.
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we were unable to do this, as in both cases (rescued and not rescued
patient’s myoblasts) a-dystroglycan glycosylation was immature
(Fig 9B). Next, we examined whether inhibition of Notch signaling
leads to altered pattern of a-dystroglycan glycosylation during dif-
ferentiation. To this end, we differentiated C2C12 cells with medium
containing DAPT or LY3039478 to decrease Notch signaling. The
cells showed a reduced expression of glycosylated a-dystroglycan at
all differentiation days (Fig 9C–F). These results support the notion
that a-dystroglycan hypoglycosylation is the consequence of Notch
inactivation, produced by the reduced activity of POGLUT1 in the
case of our patients.
Discussion
Transgenic mice in which the pan-Notch inhibitor dnMAML1 is
specifically expressed in muscle SC were recently shown to display
reduced PAX7 expression in SC cells and muscular dystrophic
features even without experimentally induced injury (Lin et al,
2013). This study highlighted the role of Notch signaling and SCs in
repairing the muscle damage caused by regular activity in a
mammal, suggesting that a primary defect in SC maintenance
caused by decreased Notch signaling can in principle result in
muscular dystrophy. However, direct evidence from human patients
was lacking to support this notion. Here, we describe a family in
which a recessive D233E mutation severely impairs the enzymatic
activity of POGLUT1, leading to a marked reduction in Notch activa-
tion in adult muscle, a decreased pool of PAX7+ SCs, and a partial
defect of a-dystroglycan functional glycosylation. The findings in
this family sharply contrast with those in other forms of
age-matched limb-girdle muscular dystrophy, including secondary
dystroglycanopathies, which show normal levels of HES1 and PAX7
transcripts in adult muscles (Appendix Fig S9).
Although patients’ muscles display reduced glycosylation of
a-dystroglycan, several findings are inconsistent with a secondary
dystroglycanopathy. First, the patients do not have elevated creatine
kinase and muscle biopsies do not show many degenerative fibers
compared with that observed in secondary dystroglycanopathies
(Cirak et al, 2013). Second, the D233E muscles exhibit reduced
a-dystroglycan laminin-binding activity but show normal agrin-
binding and compact basement membrane ultrastructure. Although
it is known that LARGE-dependent glycosylation of a-dystroglycan
is required for the binding of both laminin and agrin, the precise
glycan structures recognized by these ligands have not been deter-
mined. Agrin, but not laminin, showed normal binding to a-dystro-
glycan in patients’ muscle, suggesting that these ligands may
recognize slightly different glycan structures on a-dystroglycan.
Third, a-dystroglycan expression and laminin binding are normal in
D233E skin fibroblasts. In contrast, other forms of dystroglycanopa-
thy usually exhibit markedly diminished or no binding for both
laminin and agrin in muscle, together with defective muscular base-
ment membrane compaction (Michele et al, 2002; Hara et al, 2011;
Willer et al, 2012; Goddeeris et al, 2013). Moreover, the published
results show that secondary dystroglycanopathies caused by muta-
tions in known genes result in reduced functional a-dystroglycan
glycosylation in patient fibroblasts, and in the majority of patients,
the level of a-dystroglycan glycosylation is comparable in fibroblasts
and skeletal muscle from the same patient (Carss et al, 2013). These
observations further support the notion that, although decreased
laminin binding in muscle is likely to contribute to pathology in our
◀ Figure 7. D233E primary myoblasts exhibit decreased proliferation and increased differentiation.A–F Proliferation assays examined proliferating (PAX7+ MyoD+, arrows), self-renewing (PAX7+ MyoD, open arrows), and differentiating (PAX7 MyoD+, arrowheads) cells
from D233E patients (n = 2), healthy controls (n = 3), and disease controls (n = 3) at 1, 4, and 8 days growing in proliferation medium. Panel (A) shows
representative images from day 8. The number of patient myoblasts is lower than that of controls at all three time points, indicating a slower proliferation rate in
patient myoblasts (B), and accordingly, the percentage of proliferating cells (C) is smaller in the patient. (D) The percentage of self-renewing cells is small in
patient’s culture, reflecting a poor capacity for maintaining the pool of quiescent SCs. In addition, the percentage of PAX7+ cells (E) is smaller in patient’s culture,
similar to what was found in adult D233E muscle (shown in Fig 5D). (F) The percentage of differentiating cells is higher in the patient. We examined proliferation
capturing 7–12 randomly fields per day and condition (mean  SEM is shown; Kruskal–Wallis with Dunn’s multiple comparisons test; scale bar, 50 lm).
G–I When myoblasts started to be confluent, the proliferation medium was replaced with differentiation medium, and the myoblasts started to fuse yielding myotubes,
which were analyzed after 4 days of differentiation. (H) The fusion index, which measures the percentage of nuclei in myotubes with respect to the total number
of nuclei in myogenic cells, was higher in D233E cultures than in controls. (I) Besides, myogenin showed increased expression in D233E myoblast cultures compared
with controls. The data support that differentiation process is facilitated in patient’s muscle. Data were collected from 3 to 10 randomly chosen areas per condition
(mean  SEM is shown; Kruskal–Wallis with Dunn’s multiple comparisons test (H) and one-way ANOVA with Bonferroni’s multiple comparisons test (I); scale bar,
50 lm).
Source data are available online for this figure.
Figure 8. Rescue experiments on immortalized primary myoblasts by lentiviral infection.
A–C We overexpressed NICD in immortalized primary myoblasts to rescue the features displayed by immortalized D233E myoblasts. (B) We analyzed the proliferation at
1, 3, and 5 days, and proliferation rate in patient-LV-NICD-GFP reached the level observed in control-LV-GFP, which were higher than in patient-LV-GFP. (C)
However, the percentage of PAX7+ cells in patient-LV-NICD-GFP showed the same reduced value as in patient-LV-GFP, which were significantly lower than in
control-LV-GFP. The majority of control myoblasts were proliferating cells (PAX7+ MyoD+, arrows), with no quiescent cells and few differentiating cells (PAX7
MyoD+, arrowheads) detected. Data were collected from n = 2 independent assays (5–8 images per condition). Mean  SEM is shown; one-way ANOVA with Tukey
multiple comparisons test (B) and Kruskal–Wallis with Dunn’s multiple comparisons test (C); scale bar, 50 lm.
D–F As previously described in patient’s primary myoblasts, patient-LV-GFP myoblasts showed a striking facilitated differentiation compared with control-LV-GFP
myoblasts. This phenotype fully disappeared in patient-LV-GFP-NICD myoblasts, as quantification of the fusion index (E), and myogenin expression (F)
demonstrated. The data support a pathogenic role for Notch inhibition on the altered differentiation in our patients. Data were collected from n = 3 independent
assays (13–17 images per condition). Mean  SEM is shown; Kruskal–Wallis with Dunn’s multiple comparisons test; scale bar, 50 lm.
Source data are available online for this figure.
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patients, a-dystroglycan hypoglycosylation might not be the disease
mechanism caused by the D233E mutation, or at least the primary
mechanism.
Strikingly, our data suggest that the D233E mutation causes
defects in SC proliferation and differentiation. The amount number
of SCs in our patients is significantly reduced even in very early
stages when the muscle is barely affected, compared with healthy
and disease controls. Alterations in SC proliferation have been
described in the Largemyd mouse dystroglycanopathy model and are
thought to contribute to myodegeneration in these animals (Ross
et al, 2012). In this model, SCs are significantly increased at early
stages and have reduced proliferation when cultured on freshly
isolated single fibers; however, proliferation is restored in culture
when SCs are removed from the fibers, indicating that rather than
intrinsic defects in myoblasts, compositional changes in the extra-
cellular matrix due to hypoglycosylated a-dystroglycan are responsi-
ble for the proliferative alteration. In contrast, myoblasts from our
patients displayed reduced proliferation and self-renewal capacity in
culture when removed from their fiber niche, supporting an intrinsic
defect in D233E myoblasts independent of a-dystroglycan hypo-
glycosylation. Moreover, it has been recently demonstrated in
dystroglycanopathy mice models that functional glycosylation of
A
C
E F
D
B
Figure 9. Effects of decreased Notch signaling on a-dystroglycan glycosylation during differentiation.
A Immortalized primary myoblasts from a healthy control showed a progressive pattern of a-dystroglycan glycosylation during 5 days of differentiation (D0–D5), as
has been previously described by Goddeeris et al (2013). Immortalized primary myoblasts from patients displayed an irregular pattern of glycosylation, with a final
level of glycosylated a-dystroglycan that was lower than control.
B a-dystroglycan glycosylation of infected immortalized myoblasts from patient-LV-NICD-GFP at differentiation day 5 (D5) showed a striking reduction, in line with
the strong inhibition of myotubes formation and differentiation induced by NICD overexpression. a-dystroglycan in myoblasts from patient-LV-GFP showed a
reduction in glycosylation compared with control-LV-GFP at D5, similar to the results obtained in the adult muscle from patients (Fig 2).
C, D C2C12 myogenic cells showed a reduced level of glycosylated a-dystroglycan when the Notch signaling inhibitor DAPT or LY3039478 was added to the
differentiation medium. This indicates that reducing Notch signaling can affect a-dystroglycan glycosylation in wild-type C2C12 myoblasts cells, which do not
harbor any known mutations in a-dystroglycan glycosyltransferases or Poglut1.
E, F qRT–PCR experiments show that upon DAPT or LY3039478 treatment, a remarkable decrease in Hes1 mRNA is induced in C2C12 cells during differentiation. Three
replicates per condition were analyzed; mean  SEM is shown.
Source data are available online for this figure.
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a-dystroglycan does not play a significant role in myogenic cell
proliferation and differentiation (Awano et al, 2015). Our results
indicate that the D233E mutation results in deficient Notch signaling
in patient muscle and an impairment in the regulation of myoblast
differentiation and that expression of NICD rescues this phenotype.
Our results strongly suggest that impaired myogenesis mediated by
decreased Notch signaling is a causal mechanism of muscular
dystrophy in our patients (Fig 8). Although we expected that the
reduction in PAX7+ cells in our patients would be a direct effect of
Notch inhibition, the lack of rescue of PAX7+ cells by NICD overex-
pression suggests something more complicated. The effect of Notch
on PAX7 expression has been reported to be weaker in myogenic
cell lines than in primary myoblasts, and this could be affecting the
rescue of PAX7+ cells in our system (Sun et al, 2008). Nevertheless,
our data consistently demonstrated a decreased number of PAX7+
cells in D233E patients, compared with healthy and disease controls,
including secondary dystroglycanopathies. This result together with
a previous report showing that the blockade of Notch signaling in
muscle SCs of a mouse model causes muscular dystrophy and
impairs muscle regeneration (Lin et al, 2013) supports our hypothe-
sis that impaired regulation of muscle SC homeostasis plays a patho-
genic role in this new muscle dystrophy. Recent findings
demonstrate that the overexpression of Jagged1, a major ligand of
the Notch signaling pathway, ameliorates the dystrophic phenotype
in the golden retriever muscular dystrophic dogs, which is an excel-
lent model to the human dystrophynopathy, indicating that the
Notch pathway can be considered a new therapeutic target in
muscular dystrophies (Vieira et al, 2015).
POGLUT1 specifically adds O-glucose or O-xylose to properly
folded EGF repeats containing the CXSX(P/A)C consensus sequence
(Rana et al, 2011; Takeuchi et al, 2011, 2012) and is among the
glycosyltransferases that directly add sugar molecules to an amino
acid, not to other sugars. Therefore, since a-dystroglycan lacks EGF
repeats and the CXSX(P/A)C consensus sequence, POGLUT1 is
highly unlikely to directly add carbohydrates to a-dystroglycan core
protein or to extend the carbohydrate chains added to a-dystroglycan
by other glycosyltransferases. This is supported by our observation
that glycosylation of a-dystroglycan from D233E skin fibroblasts is
normal. These data strongly argue that POGLUT1 does not partici-
pate in the biosynthesis of the O-mannose glycans on a-dystroglycan.
Therefore, unlike POMT1/2 and LARGE which add carbohydrates to
a-dystroglycan to regulate muscle maintenance, POGLUT1 most
likely glycosylates other target proteins to maintain muscle integrity.
This notion is supported by our fly experiments: Loss of POGLUT1
enzymatic activity in Drosophila also causes a severe decrease in the
number of Twist+ myoblasts and muscle development, which can
be fully rescued by wild-type human-POGLUT1 but only weakly so
by POGLUT1D233E. However, Drosophila dystroglycanopathy models,
including null alleles of dystroglycan, do not have defects in
myoblast migration and myofiber formation (Nakamura et al, 2010),
indicating that the muscle phenotypes observed in rumi flies are not
caused by alterations in dystroglycan.
Fourteen Drosophila proteins and about 50 mammalian proteins
have EGF repeats with a CXSX(P/A)C consensus sequence and are
therefore predicted to be modified by POGLUT1 (Jafar-Nejad et al,
2010; Rana et al, 2011; Haltom et al, 2014). This consensus motif is
highly predictive of enzymatic modification, as mass spectrometric
analyses have demonstrated that most if not all EGF repeats with a
CXSX(P/A)C motif examined so far are O-glucosylated (Hase et al,
1988; Acar et al, 2008; Fernandez-Valdivia et al, 2011; Rana et al,
2011; Lee et al, 2013; Haltom et al, 2014; Ramkumar et al, 2015;
Thakurdas et al, 2016). Agrin, which is implicated in muscle
disease, is predicted to have a single POGLUT1 target site. However,
we did not observe any defects in agrin’s level, molecular size, or its
capacity to bind a-dystroglycan in our patient muscles, strongly
suggesting that impaired agrin glycosylation cannot explain the
muscular dystrophy in our patients. Indeed, the addition of O-glucose
to a target protein by POGLUT1 does not necessarily indicate func-
tional importance. For example, even though Drosophila Crumbs is
O-glucosylated, homozygosity for a knock-in allele of the Drosophila
crumbs in which all seven Crumbs O-glucosylation sites are mutated
does not recapitulate crumbs loss-of-function phenotypes during fly
development and generates viable and fertile adults (Haltom et al,
2014). Among the confirmed POGLUT1 biochemical targets, Droso-
phila Notch, mouse Notch1, mouse CRUMBS2, and Drosophila Eyes
shut are shown to be functionally regulated by POGLUT1-mediated
glycosylation (Acar et al, 2008; Fernandez-Valdivia et al, 2011;
Leonardi et al, 2011; Haltom et al, 2014; Ramkumar et al, 2015).
Moreover, there is evidence suggesting that mouse JAG1 might also
be a biologically relevant target of POGLUT1, although further exper-
iments are required to prove this (Thakurdas et al, 2016). Based on
the severe decrease in Notch signaling and Notch1 cleavage in
our patients’ muscle, the dramatic decrease in the ability of
POGLUT1D233E to glycosylate Notch EGF repeats, and previous obser-
vations on the role of POGLUT1 and Notch receptor O-glucosylation
in Notch signaling (Acar et al, 2008; Fernandez-Valdivia et al, 2011;
Leonardi et al, 2011; Ma et al, 2011; Rana et al, 2011), we propose
that the Notch receptors are the key target of POGLUT1 in the
muscle. However, we cannot exclude that other POGLUT1 targets
might also contribute to the phenotypes observed in our patients.
If POGLUT1 affects a glycosylation pathway unrelated to the O-
mannose glycans, it raises the question of why O-mannose glycosy-
lation on a-dystroglycan is impaired in D233E muscle. Our data
strongly favor an indirect mechanism for a-dystroglycan hypoglyco-
sylation, likely due to altered myogenesis caused by decreased
Notch signaling resulting from the D233E mutation. Indeed, a recent
report showed that a-dystroglycan glycosylation is at a low level
during the first stages of muscle regeneration even in wild-type mice
and is increased as myogenesis proceeds (Goddeeris et al, 2013).
The authors proposed that coordination between myogenic differen-
tiation and increased expression of the glycosyltransferase LARGE
results in bulkier a-dystroglycan molecules with more extensive
LARGE-mediated glycosylation and thereby a more robust ligand-
binding capacity during muscle repair (Goddeeris et al, 2013).
Accordingly, a-dystroglycan hypoglycosylation in our patients can
be a consequence of altered SC homeostasis and differentiation,
which would impede muscle repair and potentially result in imma-
ture LARGE-mediated glycosylation (Fig 9). Previous data show that
an adequate balance of Notch activation is needed during myogene-
sis (Kuang et al, 2007; Sacco et al, 2008), and our results support
an additional critical role of Notch signaling in the process of
a-dystroglycan glycosylation during muscle differentiation.
Nonetheless, the muscle-specific a-dystroglycan hypoglycosylation
could contribute to muscle dystrophy in our patients.
An autosomal-dominant dermatosis has recently been associated
with heterozygous mutations in POFUT1 (protein O-fucosyltransferase
EMBO Molecular Medicine Vol 8 | No 11 | 2016 ª 2016 The Authors
EMBO Molecular Medicine POGLUT1 gene mutation and muscular dystrophy Emilia Servián-Morilla et al
1302
1, which adds O-fucose to Notch), and POGLUT1 (Li et al, 2013;
Basmanav et al, 2014). Drosophila Pofut1 has a chaperone-like
function on the Notch protein independent of its O-fucosyltransferase
activity (Okajima et al, 2005). Therefore, since patients homozygous
for D233E have deficient enzymatic activity but normal POGLUT1
expression and no skin abnormalities, this dermatosis could be due to
a defect in a non-enzymatic function of POGLUT1. However, genetic
background differences could also exist that make these patients more
sensitive to a 50% reduction in POGLUT1 enzymatic activity.
In conclusion, we identified the human POGLUT1 D233E
mutation that impairs Notch posttranslational modification and
maintenance of muscle stem cells and leads to muscular degener-
ation and a-dystroglycan hypoglycosylation. Our findings demon-
strate that D233E mutation in POGLUT1 causes autosomal
recessive limb-girdle muscular dystrophy and implicate a primary
defect in muscle progenitor cells as a novel pathomechanism for
muscular dystrophy. Our patients display an adult-onset pure
muscular phenotype, in contrast to the lethal, multisystemic
phenotypes observed in animals with complete loss of POGLUT1
(Acar et al, 2008; Fernandez-Valdivia et al, 2011). Thus, the resid-
ual O-glucosyltransferase activity in our patients is sufficient for
other aspects of human development and tissue homeostasis,
indicating that myoblasts are particularly sensitive to decreased
POGLUT1 activity.
Materials and Methods
Skeletal muscle histology and ultrastructural study
Open muscle biopsies were obtained from biceps brachii or quadri-
ceps of the four patients and the healthy sibling in generation II of
the family. The muscle was rapidly frozen in liquid nitrogen-chilled
isopentane and 7-lm-thick cryostat sections were stained for stan-
dard histological and histochemical techniques including hema-
toxylin and eosin, Gomori trichrome, nicotinamide adenine
dinucleotide dehydrogenase (NADH), and ATPase pH 9.4. Stained
sections were evaluated with an Olympus BX41 (Tokyo, Japan)
equipped with a ColorView IIIu camera (Olympus).
A piece of muscle from each biopsy was fixed in glutaraldehyde,
embedded in Embed 812 resin, and processed for electron micro-
scopy by standard methods (Malfatti et al, 2013). Ultrathin sections
were viewed with Philips CM10 electron microscope (Eindhoven,
Netherlands) equipped with Gatan 1k CCD camera.
Antibodies
The list of the primary antibodies used in this study is provided in
Appendix Table S7. The anti-a-dystroglycan core protein (a kind
donation from S. Kro¨ger) sheep polyclonal antibody was raised
against a synthetic peptide corresponding to the carboxy-terminal
20 amino acids of chick a-dystroglycan (Herrmann et al, 2000).
Immunohistochemical studies
Unfixed frozen muscle sections were incubated with primary anti-
bodies overnight at 4°C, and then with the appropriate secondary
antibodies for 30 min.
Cultured myoblasts were permeabilized in 0.2% Triton X-100 for
10 min and incubated in 1% BSA/PBS for 45 min; frozen sections
were incubated in 5% normal goat serum/PBS for 45 min. Primary
antibodies were used as described in Appendix Table S7 and incu-
bated for 12 h at 4°C. After washing, samples were incubated with
the appropriate secondary antibodies for 1 h.
PAX7 immunohistochemistry was carried out according to an
antigen retrieval protocol, modified from Song et al (2012). Briefly,
samples were fixed with 4% paraformaldehyde, pH = 7.4 (PFA) for
15 min. Sections were then immersed in citrate buffer (pH 6) for
30 min at 80°C and washed with PBS. Afterward, tissue samples
were blocked with non-fat milk at 2% in PBS for 30 min and
washed with PBS. Next, tissue sample were incubated with primary
antibody for 2 days and secondary antibody for 2 h in blocking
solution (5% BSA, 0.5% Triton X-100 in PBS). aDG-CORE immuno-
histochemistry required incubation with both biotinylated
secondary antibody for 30 min and streptavidin conjugated to Cy3
for 15 min in PBS. Finally, the nuclei were stained for 20 min with
To-pro-3-Iodide (Topro) at 1:1,000 in PBS and the slides were cover-
slipped with fluorescence mounting medium (Dako). The images
were acquired on a Zeiss LSM 710 confocal laser scanning micro-
scope. Maximal projections of Z-stacked images were obtained and
analyzed with ImageJ software.
Glycoprotein enrichment and Western blot analysis
Frozen muscle samples and fresh skin fibroblasts were homoge-
nized in RIPA buffer (20 mM Tris–HCl pH 7.4, 150 mM NaCl, 1 mM
EDTA, 1% IGEPAL, 0.1% SDS) containing protease inhibitor
mixture. Western blots of glycoproteins were enriched with wheat-
germ agglutinin (WGA) agarose (Sigma-Aldrich) as described previ-
ously (Michele et al, 2002). Equivalent amounts of protein lysates
non-incubated or incubated with WGA agarose beads were resolved
on 7–10% SDS–PAGE gels and transferred to PDVF membranes
(Millipore). Immunoreactivity was detected with secondary antibod-
ies conjugated to horseradish peroxidase (Jackson Immuno
Research) and developed with SuperSignal West Femto (Thermo
Scientific) using an ImageQuant LAS 4000 MiniGold System (GE
Healthcare).
Ligand overlay assay
Ligand overlay assays in muscle and skin fibroblasts were
performed as previously described with minor modifications
(Michele et al, 2002; Willer et al, 2012). Briefly, PVDF membranes
were incubated with Engelbreth-Holm-Swarm laminin (Sigma-
Aldrich) or agrin (R&D Systems), overnight at 4°C in laminin-
binding buffer. Then, membranes were washed and incubated with
anti-agrin (Millipore) or anti-laminin (Sigma-Aldrich) primary anti-
bodies and their corresponding secondary antibodies. Blots were
imaged using the protocol described for Western blots.
Flow cytometry
The following method was modified from Stevens et al (2013b).
Briefly, an anti-a-dystroglycan antibody IIH6 was used to assess the
amount of a-dystroglycan glycosylation in fibroblasts from patients
(II.4 and II.5) and two controls. Fibroblasts (passages 2–3) were
ª 2016 The Authors EMBO Molecular Medicine Vol 8 | No 11 | 2016
Emilia Servián-Morilla et al POGLUT1 gene mutation and muscular dystrophy EMBO Molecular Medicine
1303
grown until approximately 90% confluent. Cells were detached
using Accutase (Sigma, UK), centrifuged for 3 min at 500 g, and
counted and resuspended in PBS to a final density of 200,000 fibrob-
lasts per milliliter, centrifuged at 3,000 g for 3 min, and incubated
on ice with IIH6 for 30 min, anti-mouse biotinylated IgM (Vector
Labs, USA) for 20 min, and streptavidin-PE (BD Pharmingen, UK)
for 15 min. After washing, cells were resuspended in 500 ml of PBS
and transferred to FACS tubes (Corning Science, Mex). Data were
acquired using the BD FACS Canto II analyzer and analyzed using
the BD FACSDiva software (BD Bioscience, US). Two separate
controls for each fibroblast population were used: one without any
staining to remove background and another without the primary
antibody to gate the IIH6-positive population. A total of 50,000 cells
were analyzed per experiment. We assessed the percentage of IIH6-
positive cells as well as the level of IIH6 the mean fluorescence
intensity (MFI).
Genetic mapping
Genomewide genotyping using the Illumina Infinium HumanOmni1-
Quad, v1.0 BeadChip (Illumina, San Diego, CA, USA) was
performed in the DNA samples of the four affected siblings (II.1,
II.2, II.4, and II.5) and the unaffected sister (II.3), thus allowing the
analysis of over one million assays for each sample. The chips were
scanned, and data were loaded into Illumina Genome Studio
V2009.1 software. Genome Viewer tool was used to visualize
genomic copy number variation as well as individual genotypes.
Log R ratio and B allele frequency, plotted along the entire genome
for all SNPs on the array, were used to analyze all variants. CNV
partition 2.4.4 was employed to automatically detect copy number
variants as well as regions of extended homozygosity > 500 kb
across the genome. Genotype success rates > 99.7% were obtained
for all assays (Appendix Fig S6).
Exome sequencing
The capture and subsequent sequencing of exonic regions of
DNA samples II.3, II.4, and II.5 was performed at Otogenetics Co
(Norcross, GA, USA) using the solution-based SeqCap EZ Human
Exome Library v2.0 (Roche NimbleGen, Madison, WI, USA) and
the Illumina HiSeq2000, with 100 paired-end runs. An average
coverage of 30× across the exome was achieved for all samples.
Reads were aligned to the reference genome hg19 with DNAnexus
software (Palo Alto, CA, USA) using default parameters. Single
nucleotide polymorphisms and indels were identified and realigned
using the Genome Analysis Toolkit (GATK). In order to discard
common variants, genetic variations were further verified in the
Database of Single Nucleotide Polymorphisms (dbSNP Build ID:
137; http://www.ncbi.nlm.nih.gov/SNP/), the exome variant
server (EVS) of the National Heart, Lung, and Blood Institute
GO Exome Sequencing Project (Seattle, WA, USA; http://evs.gs.
washington.edu/EVS/), and the 1000 Genomes Project (http://
www.1000genomes.org/).
Segregation analysis
Segregation analysis was performed by means of Sanger sequencing
using the primers presented in Appendix Table S4. Cycle sequencing
was performed using the Dye Terminator Sequencing Kit (Applied
Biosystems, Foster City, CA) and run on an ABI 3100 genetic
analyzer. Sequence chromatograms were analyzed using the
Sequencher software (Genecodes, Ann Arbor, MI).
Genotyping
Genotyping of the p.D233E mutation in POGLUT1 gene in the Span-
ish and the Human Genome Diversity Project series was carried out
by real-time PCR using a custom TaqMan Genomic Assay (Applied
Biosystems, Foster City, CA) with appropriate primers and probes
(Appendix Table S5). Thermal cycling and end-point polymerase
chain reaction (PCR) analysis was performed on a real-time PCR
instrument (ABI 7900HT, Applied Biosystems, Foster City, CA).
DNA from family members II.3 and II.4 was used as positive
controls in all experiments.
POGLUT1 subcloning and mutagenesis
Human POGLUT1 cDNA cloned into the pEZ-M02 vector was
obtained from GeneCopoeia (Rockville, MD, USA). The p.D233E
mutation was introduced with the QuikChange II site-directed muta-
genesis kit (Agilent Technologies, Santa Clara, CA, USA), as per
manufacturer’s indications, and confirmed by direct sequencing.
The oligonucleotide sequences used for site-directed mutagenesis
and Sanger sequencing were as follows: POGLUT1 50-CAGCCTCCG
GACTCTAGC-30 and 50-TAATACGACTCACTATAGGG-30 for wild-
type and POGLUT1 50-TCTCGGAAAAACCCAAAACTTGTTGAGGC
AGAATACACCAAA-30 and 50-TTTGGTGTATTCTGCCTCAACAAGTT
TTGGGTTTTTCCGAGA-30 (mismatched nucleotide to the reference
sequence is underlined) for the D233E mutant. cDNAs encoding the
luminal domains of wild type and D233E mutant of human
POGLUT1, starting from Arg24, were amplified by PCR using the
primers, 50-ATATATAAGCTTCACGCCAGAAGGAGTCAGGTT-30 and
50-ATCTAGCTCGAGCTAGTTCAGTTTTCAACATTTTGGG-30, and
subcloned into a pSecTag2c vector (Invitrogen) in frame with a
C-terminal Myc/6xHis tag for expression in mammalian cells. The
expression constructs for wild-type human POGLUT1 in pcDNA4 or
pTracer vector were also used as a template for site-directed muta-
genesis to introduce the D233E mutation (Rana et al, 2011;
Takeuchi et al, 2012). The sequences of the primers are 50-CT
TGTTGAGGCAGAATACACCAAAAACCAGGCCTG-30 and 50-GTATT
CTGCCTCAACAAGTTTGGGTTTTTCCGAGACAG-30. The pcDNA4-
based construct encodes the recombinant protein with a C-terminal
Myc/6xHis tag. The pTracer-based construct encodes the recombi-
nant protein with a FLAG tag, which is immediately downstream of
the KTEL sequence at the C-terminus. Successful incorporation of
the mutation was confirmed by direct DNA sequencing.
In vitro glycosylation assays
Myc/6xHis-tagged POGLUT1 proteins were expressed in HEK293T
cells by transient transfection, and the secreted proteins were puri-
fied from the culture media using Ni-NTA agarose (QIAGEN).
POGLUT/POXYLT assays were performed as previously described
(Fernandez-Valdivia et al, 2011). Briefly, a 10 ll standard reaction
mixture contained 50 mM HEPES pH 6.8, 10 mM MnCl2, the indi-
cated amounts of acceptor substrates, 0.16 lM UDP-[6-3H]glucose
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(2.22 TBq/mmol), 10 lM UDP-glucose, 0.5% Nonidet P-40, and
purified proteins. For POXYLT assay, 10 lM UDP-[14C(U)]xylose
(5.43 GBq/mmol) was used as donor substrate. The reaction was
performed at 37°C for 20 min and stopped by adding 900 ll of
100 mM EDTA pH 8.0. The sample was loaded onto a C18 cartridge
(100 mg, Agilent Technologies). After the cartridge was washed with
5 ml of H2O, the EGF repeat was eluted with 1 ml of 80% methanol.
Incorporation of [6-3H]glucose or [14C(U)]xylose into the EGF repeats
was determined by scintillation counting of the eluate. Reactions
without substrates were used as background control. Data are from
three independent assays. The values indicate mean  SEM.
O-glucosylation or O-xylosylation of human factor IX EGF repeat
and EGF16 from mouse Notch2 was performed using a modified
POGLUT/POXYLT assay. A 100 ll reaction mixture contained
50 mM HEPES pH 6.8, 10 mM MnCl2, 10 lM acceptor substrate,
200 lM UDP-glucose, and purified wild-type or D233E mutant
POGLUT1. For O-xylosylation, 200 lM UDP-xylose was used as
donor substrate. Approximately 500 ng of each recombinant enzyme
was used. The reaction was performed at 37°C overnight. The reac-
tion products were purified by reverse-phase high-performance
liquid chromatography (RP-HPLC, Agilent Technologies, 1200
Series) equipped with a C18 column (10 × 250 mm, VYDAC) with a
linear gradient of solvent B (80% acetonitrile, 0.1% trifluoroacetic
acid (TFA) in water) from 10 to 90% in solvent A (0.1% TFA in
water) for 60 min, monitoring absorbance at 214 nm. Elution pro-
files between 20 and 30 min are shown as milli-absorbance unit
(mAU). Peak fractions were pooled, dried down in a Speed-Vac
centrifuge, and stored at 20°C for further mass spectral analysis.
Mass spectrometric analysis of glycosylation products
Mass spectrometric analysis by infusion was performed as described
previously (Takeuchi et al, 2012). Briefly, dried samples were resus-
pended in 0.1% formic acid in water, spin-filtered, and injected into
an Agilent 6340 ion-trap mass spectrometer with a nano-HPLC
CHIP–Cube interface at a rate of 18 ll/h. The MS peaks for MS/MS
were chosen manually, and the data were analyzed using Agilent
ChemStation data analysis software. The masses of EGF repeats
with different charge states were deconvoluted and shown on the
top of peaks in HPLC profiles.
RT–PCR and qRT–PCR analysis
Total RNA was extracted using QIAzol and RNeasy kit (Qiagen).
cDNA was synthesized from 1 lg of total RNA using Transcriptor
First Strand cDNA Synthesis Kit (Roche). qRT–PCR (100 ng total
cDNA per reaction) was performed using TaqMan Fast Advanced
Master Mix (Applied Biosystems) in a 7500 Fast Real-Time PCR
System. Relative mRNA levels were compared using the 2DDCT
method, with GAPDH as control (only POGLUT1 mRNA level was
relative to desmin). We used TaqMan probes (Applied Biosystems)
for human HES1 (Hs00172878_m1), human PAX7 (Hs0024
2962_m1), human POGLUT1 (Hs00220308_m1), human GAPDH
(Hs02758991_g1), human DES (Hs00157258_m1), mouse HES1
(Mm01342805_m1), mouse Pax7 (Mm01354484_m1), and mouse
GAPDH (Mm03302249_g1).
We selected the disease control muscles from patients with well-
characterized limb-girdle muscular dystrophies. To avoid possible
differences due to the effect of age on the satellite cell population
(Chakkalakal et al, 2012; Sousa-Victor et al, 2014), our samples of
D233E patients and both healthy and disease controls were age-
matched (Appendix Table S6).
Generation of the transgenic fly
To generate transgenic flies capable of overexpressing human
POGLUT1D233E, a BamHI-XbaI fragment containing the
POGLUT1D233E ORF was released from pTracer-POGLUT1D233E-
FLAG and cloned into the BglII-XbaI sites of pUASTattB (Bischof
et al, 2007) to generate pUASTattB-POGLUT1D233E-FLAG. Genera-
tion of pUASTattB-POGLUT1wt-FLAG was described previously
(Fernandez-Valdivia et al, 2011). Both constructs were integrated
into the VK22 docking site by using ΦC31-mediated transgenesis
to generate UASattB-POGLUT1D233E-FLAG.VK22 and UASattB-
POGLUT1WT-FLAG.VK22 transgenes. Correct integration events were
verified by att PCRs, as described previously (Venken et al, 2006).
Analysis of muscle phenotype in Drosophila
We assessed the effect of POGLUT1 activity toward the development
of indirect flight muscles in Drosophila (Gildor et al, 2012). Rescue
experiments were performed with fly transgenes expressing human
POGLUT1wt (wild type) and human POGLUT1D233E. w1118 (wt),
rumi79/79, Mef2-GAL4/UASattB-POGLUT1WT-FLAG; rumi79/79, and
Mef2-GAL4/UASattB-POGLUTD233E-FLAG; rumi79/79 animals were
raised at 18°C until puparium formation. Pupae 0–1 h after pupar-
ium formation (APF) were incubated at indicated temperatures until
25% pupal development. Pupal indirect flight muscles were
dissected and stained using standard methods. Antibodies are rabbit
a-Twist 1:5,000 (Roth et al, 1989), mouse 22C10 1:50 (DSHB),
mouse a-FLAG M2 1:100 (Sigma), donkey-a-rabbit-Cy3 1:500,
donkey-a-mouse-Cy5 1:500 (Jackson ImmunoResearch Laborato-
ries). Confocal images were scanned using a Leica TCS-SP5 micro-
scope and processed with Amira5.2.2. Myotube lengths were
measured using a two-dimensional measurement tool in Amira5.2.2.
Mean myotube lengths and standard deviations were calculated for
rumi79/79 pupae with no rescue and rumi79/79 pupae overexpressing
POGLUT1WT (n = 22) or POGLUT1D233E (n = 54). One-way ANOVA
with Tukey’s multiple comparisons test was used to determine the
P-values. Images were processed with Adobe Photoshop CS5;
figures were assembled in Adobe Illustrator CS5.
C2C12 cell line culture and Notch inhibition assay
C2C12 cell line was cultured in monolayer. The culture media for
the C2C12 myoblast stage contains Dulbecco’s minimal essential
medium (DMEM, Gibco, BRL, Bethesda, MD), supplemented with
5% glutamine, 10% fetal bovine serum, 1% penicillin–strepto-
mycin–fungizone, and 23 mM HEPES. The cultures were examined
regularly to avoid overgrowth. For the Notch inhibition assay, we
treated C2C12 myoblasts at 80–90% confluence with DAPT (Sigma-
Aldrich, USA), a c-secretase inhibitor, and a well-established inhi-
bitor of Notch, a c-secretase substrate, as previously published
(Kuang et al, 2007). We also treated C2C12 myoblasts with
LY3039478 (ApexBio Technology LLC), a more specific and potent
Notch inhibitor. For this experiment, culture proliferation and
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differentiation medium were modified by adding 50 lM DAPT or
25 lM LY3039478, and 50–25 lM DMSO for controls, respectively.
Primary cell culture
Muscle biopsies from two patients (II.4 and II.5), three age-matched
healthy controls and three age-matched disease controls were used for
the experiments. Muscle biopsies were minced and cultured in a
monolayer. Briefly, the culture medium for the myoblast stage
contains 75% Dulbecco’s minimal essential medium (Invitrogen) and
25% M199 medium (Invitrogen), supplemented with 10% fetal
bovine serum (FBS), 10 lg/ml insulin, 2 mM glutamine, 100 units/ml
penicillin, 100 lg/ml streptomycin, 0.25 lg/ml fungizone, 10 ng/ml
epidermal growth factor, and 25 ng/ml fibroblast growth factor. To
obtain highly purified myoblasts, each 107 cells were mixed with
20 ll of CD56-coated microbeads (Miltenyi Biotec, Bergisch Gladbach,
Germany) and incubated at 6–12°C for 15 min. Unbound microbeads
were removed by washing cells in excess PBS buffer followed by
centrifugation at 300 × g for 10 min. The cell pellet was resuspended
in PBS buffer to a concentration of 2 × 108 cells/ml before separation
on a midiMACS cell separator (Miltenyi Biotec, Bergisch Gladbach,
Germany). CD56-positive cells were seeded at 13,000 cells/cm2 using
the culture medium for the myoblast stage containing 15% of FBS and
without growth factors to avoid interference with the results. We
examine proliferation at different days. When the myoblasts started to
fuse, the medium was substituted with one containing 2% of FBS. We
measured the fusion index 4 days after medium change by calculating
the mean percentage of nuclei in myotubes in respect to the total
number of nuclei (myoblasts + myotubes).
Human skin biopsies were minced and cultured. Fibroblasts were
grown in DMEM containing 15% fetal bovine serum and 1% peni-
cillin–streptomycin–fungizone at 37°C with 5% CO2.
Myoblast immortalization
Myoblasts from II.4 patient and healthy control were transduced
with lentiviral vectors encoding hTERT and cdk4 containing puro-
mycin and neomycin selection markers, respectively. Transduced
cells were selected with puromycin (1 lg/ml) for 6 days and
neomycin (1 mg/ml) for 10 days. Infected cells were purified using
an immunomagnetic cell sorting system (MACS; Miltenyi) according
to the manufacturer’s instructions with anti-CD56 microbeads. Cells
were seeded at clonal density, and individual myogenic clones were
isolated and characterized.
Fibroblast myogenic conversion
Fibroblasts from II.4 patient and healthy control were transduced
with lentiviral vector encoding hTert. Transduced cells were
selected with puromycin (1 lg/ml) for 6 days. Immortalized fibrob-
lasts were then transduced with a lentiviral vector encoding indu-
cible MyoD. For MyoD induction, doxycycline (2 lg/ml) was added
in the proliferation medium (this day was considered day 0).
Lentivirus generation and infection
We generated lentiviral vectors (LV), based on the calcium phos-
phate method as previously described (Yoshida et al, 2013). Briefly,
HEK293T cells were transfected using transfer plasmids,
EF.hICN1.CMV.GFP (#17623, Addgene) or EF.CMV.GFP, together
with psPAX2 packaging and pMD2.G envelope plasmid DNA at a
ratio of 4:3:1, respectively. Then, 48 h post-transfection, medium
was collected, filtered, and concentrated by centrifugation for
90 min at 105,000 × g using a SW 32 Ti Beckman rotor. Supernatant
was completely removed and pellet diluted in 100 ll PBS overnight
at 4°C, titered by FACS, and stored at 80°C until use. Immortalized
myoblasts from patients were infected with LV-NICD-GFP or LV-
GFP, and immortalized myoblasts from control with LV-GFP. After
7 days, GFP-positive cells were purified by FACS.
Study approval
This study was approved by the Institutional Research Ethic
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The paper explained
Problem
The fact that in a significant number of patients suffering from a
muscular dystrophy, the responsible gene is still unknown stimu-
lates research to describe new molecular and cellular pathomecha-
nisms underlying muscle degeneration. It is known that even in
healthy individuals, common daily activities cause skeletal muscle
lesions that are physiologically repaired through activation of satel-
lite cells. Accordingly, it is logical to envision a scenario where
alteration in the satellite cell homeostasis could lead to muscle
fiber degeneration because of accumulation of unrepaired damage.
Indeed, this appears to be the case with the family we present
carrying a homozygous missense D233E mutation in POGLUT1 gene:
a muscular dystrophy as a consequence of defective muscle
regeneration.
Results
It is widely known that Notch signaling pathway plays critical roles
in the highly coordinated muscle regenerative process, maintaining
an appropriate population of satellite cells and preventing prema-
ture differentiation. Our previous work in Drosophila and mamma-
lian cell lines has shown that the addition of O-linked glucose to
Notch receptors by protein O-glucosyltransferase 1 (POGLUT1; also
known as Rumi) is required for Notch signaling. In the investigated
family, a homozygous missense D233E mutation in POGLUT1
dramatically reduces its enzymatic activity on Notch. As a result,
the investigated family shows a defect in Notch signaling with a
significant depletion of satellite cells, resulting in defective muscle
regeneration and ultimately leading to muscle dystrophy. In addi-
tion, primary myoblasts from our patients displayed reduced self-
renewal capacity and enhanced differentiation in culture, as
expected under a Notch signaling defective environment. We show
that the enzymatic activity of POGLUT1 is also essential for the
formation of adult muscles by myoblasts in Drosophila. Moreover,
cross-species overexpression studies in Drosophila indicate that the
D233E mutation impairs the ability of human POGLUT1 in rescuing
the muscle defects in flies lacking endogenous POGLUT1 activity.
We have previously shown that complete loss of POGLUT1 results
in embryonic lethality, but our patients only exhibit an adult-onset
muscular dystrophy. Our data provide a clear explanation for this
apparent discrepancy: First, the D233E does not affect the expres-
sion level and the subcellular localization of POGLUT1, and second,
despite the severe decrease in the enzymatic activity of
POGLUT1D233E, this mutant protein maintains a residual activity. Of
note, our patients also exhibited a muscle-specific reduction in
glycosylation and laminin binding of a-dystroglycan. While these
defects probably contribute to muscle dystrophy in our patients, we
do not favor the hypothesis that they constitute the primary
underlying mechanism for the disease, as a-dystroglycan lacks
POGLUT1 target sites and patient fibroblasts show normal a-dystro-
glycan glycosylation and laminin binding. Instead, we propose that
altered proliferation and differentiation of satellite cells due to
decreased Notch signaling ultimately alter the a-dystroglycan glyco-
sylation, which is a dynamic process during muscle differentiation.
Impact
Our data link a missense mutation in POGLUT1 to a novel form of
muscular dystrophy and suggest that Notch-dependent loss of
satellite cells is the primary pathomechanism for the disease in
our patients. The muscle-specific phenotypes in our patients indi-
cate that muscle stem cells are much more sensitive to a decrease
in POGLUT1 enzymatic activity compared with other human cell
types and suggest that small molecules affecting the activity of
POGLUT1 in muscle could be of potential benefit in controlling the
behavior of satellite cells, paving the way for potential future
therapies.
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